Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 2

Conditions: Peritoneal Cancer; Fallopian Tube Cancer; Ovarian Cancer; Neoplasms, Ovarian

Treatments: Drug: Topotecan; Drug: Gemcitabine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00061308

104864/627

Details and patient eligibility

About

This research study was designed to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer, as well as tumors of mixed mullerian origin. Additional purposes are to determine the long term outcome and side effects of this combination treatment.

Since topotecan and gemcitabine have different mechanisms of action, the combination of these 2 drugs may provide better results than either drug alone. Prior studies suggest that the combination of topotecan and gemcitabine improves the effects on the tumor and also appeared to be well tolerated.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease.
• At least 4 weeks since last surgery or radiation therapy.
• Must have had a treatment-free interval of greater than 6 months following response to platinum.
• ECOG performance status of 0,1, or 2.

Exclusion criteria

• Women of child-bearing potential that do not practice adequate contraception.
• Pregnant or lactating.
• Received more than one primary chemotherapy regimen.
• Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.
• Active uncontrolled infection requiring antibiotics.
• Concurrent severe medical problems unrelated to the malignancy which would limit full compliance with the study.
• Received radiation to more than 10% of bone.
• Prior treatment with topotecan or gemcitabine.
• Hypersensitivity to camptothecin or nucleoside analogues.
• Use of an investigational agent within 30 days.